Rankings
▼
Calendar
▼
FLNA FY 2021 Earnings Report — Filana Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Filana Therapeutics, Inc.
FLNA
FY 2021 Earnings
Reported December 31, 2021
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
FY 2021
Prior Q
FY 2020
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$33M
—
—
—
—
EPS (Diluted)
$-0.82
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$25M
Selling & Marketing
$0
General & Administrative
$8M
SG&A Expenses
$8M
Other Expenses
$0
Operating Expenses
$33M
Cost & Expenses
$33M
OPERATING INCOME
-$33M
Interest Income
$49.0K
Interest Expense
$0
Other Income/Expenses
$483.0K
INCOME BEFORE TAX
-$32M
Income Tax Expense
$0
Net Income from Continuing Ops
-$32M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$32M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$32M
D&A
$534.0K
EBIT
-$33M
EBITDA
-$32M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
← FY 2022
FLNA Overview